obesity drug news today glp-1 2025 sep 30 Market Size to Hit USD 66.57 Billion by 2035 This new Medicare program offers

That being said the usual big 4 of nausea, vomiting, diarrhea and constipation lead the charge here as usual

While GLP-1RAs have been linked to a statistically significant elevation in the risk of early-stage DR events compared to placebo, they may conversely demonstrate a protective effect against the progression to advanced-stage diabetic retinopathy when compared to insulin therapy [81]

So far, the trials seem to show: high reduction in weight, hovering around 28% for those on a 12-milligram dose self-reported improvements in cardiometabolic risk factors like high blood pressure, insulin, and fasting glucose promising results for type 2 diabetes and fatty liver disease a reduction in pain from knee osteoarthritis Retatrutide may be valuable for those who have had limited success with other weight loss drugs, have a higher BMI, or are at significant metabolic risk

The DURATION-8 trial (N=695) evaluated exenatide once weekly plus dapagliflozin and found additive HbA1c reduction (1.5% versus 1.0% for either monotherapy) without increased hypoglycemia [15]

Compared to native GLP-1, exendin-4 is more resistant to cleavage by DPP-4 due to a Gly to Ala substitution at the second position [47]